PTSD: trauma-focused therapy first — the AU general practice approach

What PTSD is — and why the right treatment matters

Post-traumatic stress disorder (PTSD) is one of the most consequential mental health conditions in Australian general practice — and one of the most treatable. Around 12% of Australians will meet criteria for PTSD at some point in their lifetime; approximately 5% are affected at any given time, per the ABS National Study of Mental Health and Wellbeing. The condition concentrates in specific populations: veterans (10–20% lifetime prevalence), police and emergency services, refugees, survivors of intimate-partner and sexual violence, and Aboriginal and Torres Strait Islander communities carrying the weight of intergenerational trauma.

The core message: PTSD responds well to specific, guideline-endorsed treatments. The Phoenix Australia 2020 national guidelines — Australia’s primary clinical authority for PTSD — position trauma-focused psychological therapies as first-line, with SSRIs as an important but secondary tool. The general-practice role is diagnosis, safety assessment, Mental Health Care Plan initiation, and ensuring the patient reaches a therapist with genuine trauma expertise.

What does not work — and may harm — is routine single-session debriefing post-trauma, and long-term benzodiazepine prescribing. Both remain common in clinical practice; both are contraindicated by current evidence.

A. Core clinical — the AU general-practice framework

The DSM-5 diagnostic structure

PTSD requires exposure to actual or threatened death, serious injury, or sexual violence — directly experienced, witnessed, learned of in a close person, or through repeated extreme occupational exposure to aversive details (as occurs in first responders and forensic professionals). Four symptom clusters must be present for more than one month with significant functional impairment:

• Cluster B — Intrusion: distressing memories, recurrent nightmares, dissociative flashbacks, intense psychological distress or physiological reactions to trauma cues.
• Cluster C — Avoidance: effortful avoidance of internal reminders (thoughts, feelings, memories) and external reminders (people, places, situations, conversations).
• Cluster D — Negative alterations in cognition and mood: persistent negative beliefs about self or the world (“I am broken,” “nowhere is safe”), distorted self-blame for the trauma, persistent negative emotions, anhedonia, detachment from others, inability to experience positive emotions.
• Cluster E — Alterations in arousal and reactivity: irritability or aggression, hypervigilance, exaggerated startle response, concentration difficulties, sleep disturbance, reckless or self-destructive behaviour.

Complex PTSD (ICD-11) adds three further clusters to the core: severe and persistent affect dysregulation, a deeply negative sense of self (pervasive shame, worthlessness, guilt), and persistent difficulty sustaining close relationships. This pattern is most common after prolonged, repeated, or childhood trauma — captivity, institutional abuse, ongoing domestic violence.

Screening and assessment tools

A structured, staged approach works well in general practice:

1. PC-PTSD-5 (5-item PTSD screen for DSM-5) — quick initial screen in general practice; positive at ≥3.
2. PCL-5 (PTSD Checklist for DSM-5, 20 items) — severity measure; scores ≥31 are consistent with a PTSD diagnosis and appropriate for tracking treatment response.
3. CAPS-5 (Clinician-Administered PTSD Scale) — gold-standard structured diagnostic interview; typically administered by a trauma psychologist or psychiatrist.
4. ITQ (International Trauma Questionnaire) — screens for ICD-11 PTSD and Complex PTSD.

Ask directly about trauma history — patients rarely volunteer it. Prompt specifically around adverse childhood experiences, military or first-responder service, sexual assault, and domestic violence.

History

Per Phoenix Australia 2020, a thorough PTSD history includes:

• Trauma history — type, severity, recency, recurrence, childhood adversity, number of distinct traumas.
• Symptom profile across all four clusters, with functional impact on work, relationships, and activities of daily living.
• Suicide and self-harm risk — this is structurally essential; PTSD carries substantially elevated suicide risk and must be assessed at every presentation.
• Current safety — ongoing intimate-partner violence, active threat, or unsafe living situation.
• Comorbidities — major depressive disorder (~50% co-occurrence with PTSD), anxiety disorders, alcohol and substance-use disorders, chronic pain, traumatic brain injury, eating disorders.
• Substance use — alcohol use disorder and PTSD commonly co-occur; treat concurrently.
• Medications and treatments tried — prior SSRI trials, therapy attempts, hospitalisation history.
• Social context — housing, finances, legal proceedings, immigration status (for refugees), cultural and religious factors.

Investigations

Per eTG: Psychotropic and AMH:

• PCL-5 at baseline to document severity and track response.
• Bloods selectively: TSH, FBC, B12/folate, vitamin D; urine drug screen and blood alcohol if substance use is a concern.
• Head imaging (CT or MRI) if traumatic brain injury is possible.
• Sleep study if obstructive sleep apnoea features are present.

MBS pathways

The standard Medicare entry is a Mental Health Care Plan (MHCP) prepared under MBS item 2715 (≥20 minutes) or item 2717 (≥40 minutes), with reviews at item 2712. This opens Better Access psychology under items 80100–80170 — up to 10 individual sessions per calendar year. Since November 2025, the MHCP is only payable when the patient is registered with the practice under MyMedicare or the GP is their registered usual GP.

For PTSD alongside chronic comorbidities (chronic pain, cardiovascular disease, diabetes), a GP Chronic Condition Management Plan under items 965 and 967 (replacing retired items 721/723 from July 2025) can streamline allied health referrals.

Veterans and their immediate families access counselling through Open Arms (1800 011 046) — no DVA card required. DVA Gold and White Cards cover all PTSD-related treatment without copayment.

B. The evidence: trauma-focused therapy first

Phoenix Australia 2020, NICE NG116, the APA 2017 Clinical Practice Guideline, and the ISTSS 2018 consensus all align on the same hierarchy: trauma-focused psychological therapies are first-line for PTSD.

What works

Trauma-focused CBT (TF-CBT) encompasses two guideline-endorsed protocols:

• Cognitive processing therapy (CPT): addresses trauma-related cognitive distortions — the “stuck points” that keep PTSD going. Examples include excessive self-blame, beliefs that the world is completely dangerous, or that one is permanently damaged. CPT works through structured written accounts and Socratic questioning to challenge these beliefs.
• Prolonged exposure (PE): structured, graduated confrontation of trauma memories and reminders — imaginal and in-vivo. Helps the nervous system learn that memories are not the threat itself, and reminders can be tolerated. Takes courage; dropout is 20–40% in trials.

Eye movement desensitisation and reprocessing (EMDR): bilateral stimulation (typically eye movements, but also auditory tones or tactile taps) while holding a target trauma memory and its associated negative cognition in mind. Equivalent efficacy to TF-CBT in Cochrane reviews (Bisson et al 2013 — 70 RCTs); large effect sizes versus waitlist control.

Narrative exposure therapy (NET): particularly effective for refugees and people with multiple traumas; places life events chronologically on a timeline and integrates fragmented trauma memories into a coherent autobiographical narrative.

Typical course: 8–16 sessions with a trauma-trained psychologist. Specify “trauma-focused CBT,” “CPT,” “PE,” or “EMDR” on the Better Access referral — not every psychologist has this training. The Phoenix Australia service directory lists trained practitioners.

What doesn’t work — and may harm

Single-session psychological debriefing (Critical Incident Stress Debriefing, CISD) was historically used in emergency services and after disasters. Cochrane review (Rose et al 2002) and updated meta-analyses show no benefit and possible harm — some debriefed individuals had higher subsequent PTSD rates than controls, likely because forced retelling disrupts natural recovery in vulnerable people. Both Phoenix Australia 2020 and NICE NG116 explicitly recommend against routine single-session debriefing.

The guideline-endorsed post-trauma response is: psychological first aid (practical support, normalising responses, connection to services), watchful waiting, and formal PTSD screening at 4–6 weeks.

Long-term benzodiazepine use for PTSD hyperarousal and insomnia carries strong evidence against it. Benzodiazepines appear to impair fear extinction — the neurological mechanism that trauma-focused therapies depend on — and are associated with worse PTSD outcomes, plus dependency and cognitive impairment. SafeScript, QScript, ScriptCheck SA, and equivalent real-time prescription monitoring systems across all states must be checked before every benzodiazepine prescription. Short-term use under two weeks for acute crisis may occasionally be appropriate; long-term prescribing is strongly discouraged.

C. Pharmacotherapy in PTSD

Medications are second-line per Phoenix Australia 2020 — important in practice when therapy access is limited, when comorbid severe depression warrants an SSRI, or when acute hyperarousal needs to be managed while therapy is arranged.

Per eTG: Psychotropic and AMH:

Agent	PBS	Notes
Sertraline 50–200 mg/day	General schedule	TGA-approved for PTSD; first-choice SSRI
Paroxetine 20–60 mg/day	General schedule	TGA-approved; significant discontinuation syndrome — taper slowly
Escitalopram / fluoxetine	General schedule	Effective; escitalopram preferred in older adults
Venlafaxine XR 75–225 mg/day	General schedule	SNRI; equivalent efficacy to SSRIs
Prazosin 1–10 mg nocte	General schedule	Off-label α-1 antagonist for nightmare-predominant PTSD; titrate slowly — postural hypotension; PACT trial 2018 was negative in a large veteran cohort — Raskind et al NEJM 2018; review response at 4–6 weeks
Mirtazapine	General schedule	Sleep disturbance, comorbid depression; weight gain
Low-dose atypical antipsychotics	Authority Required	Specialist-led; refractory hyperarousal or dissociation; metabolic monitoring required

Continue effective treatment for ≥12 months after remission. Long-term SSRI monotherapy without access to trauma-focused therapy should be reviewed regularly — keep working toward therapy access.

MDMA-assisted psychotherapy

The TGA made Australia the first country to authorise MDMA prescribing for PTSD via the Authorised Prescriber pathway from July 2023. The pivotal MAPP1 and MAPP2 phase III trials (Mitchell et al Nat Med 2021; 2023) showed approximately 67% of participants no longer met PTSD criteria versus ~32% in the placebo-plus-therapy arm — a large effect size, NNT approximately 3.

However, the US FDA Advisory Committee voted against approval in August 2024, citing functional unblinding, trial-conduct concerns, and lack of independent replication outside MAPS-sponsored studies. The Australian Authorised Prescriber pathway remains active pending review. For patients considering MDMA-assisted therapy: specialist psychiatrist only, very limited AU access, out-of-pocket cost typically $25,000–35,000 per treatment course, not PBS-subsidised.

D. Australian operations

MBS billing summary

Key items for PTSD in general practice (MBS Online, verified 2026-05-21):

• Standard GP attendance: 23, 36, 44.
• MHCP preparation: 2715 / 2717; review 2712.
• Better Access psychology: items 80100–80170; 10 individual sessions per calendar year.
• GPCCMP for PTSD + chronic comorbidities: 965 (preparation), 967 (review).
• ATSI Health Assessment: 715 — key entry point for trauma history in Aboriginal and Torres Strait Islander patients.
• Telehealth: video 91890, phone 91891; existing-relationship rule applies.

If PTSD coexists with a comorbid eating disorder meeting criteria, the Eating Disorder Plan (items 90250–90263) allows up to 40 subsidised psychology sessions per year.

Veterans

Open Arms (1800 011 046) provides free counselling for veterans, their immediate families, and ex-partners with children — no DVA card required. DVA Gold and White Cards cover all PTSD-related care. The 2024 Royal Commission into Defence and Veteran Suicide has driven significant investment in streamlining DVA access and proactive mental health outreach; documentation of trauma history and treatment timelines is increasingly important.

First-responder presumptive workers’ compensation

Police, fire, paramedic, and other designated first responders in Victoria, NSW, Queensland, ACT, South Australia, and Tasmania have presumptive workers’ compensation coverage for PTSD — work-relatedness is assumed unless disproved. GPs should document trauma-relevant clinical history carefully and initiate PTSD assessment promptly; early treatment and workplace accommodation improve long-term outcomes and return-to-work rates.

SafeScript and real-time prescription monitoring

Every benzodiazepine prescription for a patient with PTSD warrants a mandatory SafeScript check (Victoria) and equivalent state RTPM. Document indication, planned duration, and cessation plan. Concurrent benzodiazepine and opioid prescribing in PTSD carries significant overdose risk and should be avoided wherever possible.

PBS

SSRIs (sertraline, escitalopram, fluoxetine, citalopram), paroxetine, venlafaxine, and mirtazapine are general-schedule PBS items — standard GP prescription, no authority required. Prazosin is general schedule (off-label for PTSD). Atypical antipsychotics (quetiapine, risperidone, olanzapine, aripiprazole) require Authority Required prescriptions when used adjunctively for PTSD; specialist initiation is expected.

E. Special populations

Veterans and ex-serving personnel. Lifetime PTSD prevalence 10–20%; combat exposure, moral injury, and operational stress compound civilian risk factors. Open Arms provides veteran-specific counselling including telehealth. Veteran-specific support programs — Soldier On, Mates4Mates, RSL Lifecare — complement clinical treatment with peer connection.

Refugees and asylum seekers. Typically carry multiple and prolonged traumas — persecution, torture, displacement, detention, and ongoing uncertainty about legal status. Specialist state-based torture and trauma services are the appropriate referral pathway: STARTTS (NSW), Foundation House (Victoria), QPASTT (Queensland), Phoenix Centre (Tasmania), STTARS (South Australia), Companion House (ACT), ASETTS (Western Australia). Narrative exposure therapy is particularly well-suited to this population.

Aboriginal and Torres Strait Islander peoples. Intergenerational trauma compounds individual trauma exposure and shapes clinical presentation. The ATSI Health Assessment (MBS 715) is a key entry point; trauma history is best raised within a culturally safe, community-led framework. 13YARN (13 92 76) provides 24-hour culturally safe crisis support run by and for Indigenous Australians.

First responders. Police, paramedics, firefighters, and corrections officers carry elevated PTSD risk from cumulative operational trauma. The Beyond Blue Police and Emergency Services program and Phoenix Australia’s first-responder resources provide peer support and education. Presumptive workers’ compensation applies in most jurisdictions — see section D.

Perinatal PTSD. Birth trauma is an underrecognised cause of PTSD. Screen with PC-PTSD-5 and Edinburgh Postnatal Depression Scale in the postnatal period. SSRI safety in breastfeeding varies by agent — per-drug review with AMH is appropriate. Specialist perinatal mental health referral is appropriate for moderate-to-severe presentations.

Children and adolescents. Child-focused TF-CBT (Child and Family version) is the guideline-recommended standard. PTSD in children may present as separation anxiety, school refusal, regressive behaviour, somatic complaints, or disruptive behaviour rather than the adult pattern. Mandatory child safety reporting applies in all Australian states and territories if children are at risk of harm.

When to escalate

Urgent (ED or same-day mental health team):

• Active suicidality or serious self-harm risk.
• Severe dissociation — derealisation or depersonalisation impairing safety.
• Acute safety risk — ongoing intimate-partner violence, active threat exposure.
• Inability to maintain basic safety or self-care.

Same-week (specialist psychiatrist or trauma psychologist):

• Complex PTSD (childhood, prolonged, or interpersonal trauma) requiring phased treatment.
• Comorbid substance-use disorder requiring concurrent specialist management.
• Treatment-resistant PTSD — partial or no response after an adequate SSRI trial plus trauma-focused therapy.
• High diagnostic uncertainty or atypical presentation.

Routine (Better Access psychology with trauma expertise):

• All confirmed PTSD for trauma-focused therapy initiation — via Mental Health Care Plan.
• Veterans: Open Arms 1800 011 046.
• Refugees: state torture and trauma service.

Crisis lines: Lifeline 13 11 14 · Beyond Blue 1300 22 4636 · 1800RESPECT 1800 737 732 · Open Arms 1800 011 046 · Suicide Call Back 1300 659 467 · MensLine 1300 78 99 78 · 13YARN (Indigenous) 13 92 76.

What this article is and is not

This is general health information drawn from the Phoenix Australia 2020 Australian PTSD Guidelines, Therapeutic Guidelines (eTG), AMH, NPS MedicineWise, NICE NG116, and current peer-reviewed evidence. It is not personal medical advice and does not create a doctor–patient relationship. Management of PTSD — including choices about specific therapies and medication — is made collaboratively between you and your own GP and mental health treating team.

For Australian consumer resources: Beyond Blue — PTSD, Black Dog Institute, HealthDirect — PTSD, Phoenix Australia, Open Arms (DVA), 1800RESPECT.

For acute mental-health crisis: Lifeline 13 11 14, Beyond Blue 1300 22 4636.

---

Sources cited

1. Phoenix Australia — Australian Guidelines for the Prevention and Treatment of PTSD (2020)
2. Therapeutic Guidelines (eTG) — Psychotropic
3. Australian Medicines Handbook (AMH)
4. RACGP
5. NPS MedicineWise
6. TGA — MDMA/psilocybin Authorised Prescriber pathway (2023)
7. Services Australia — MyMedicare
8. Services Australia — GPCCMP billing rules
9. PBS
10. NICE NG116 — PTSD
11. Cochrane — Bisson et al 2013, psychological therapies for chronic PTSD
12. Cochrane — Rose et al 2002, psychological debriefing
13. Mitchell et al — MAPP1, Nat Med 2021
14. Mitchell et al — MAPP2, Nat Med 2023
15. Raskind et al — PACT trial, NEJM 2018
16. Open Arms — DVA
17. Beyond Blue
18. Black Dog Institute
19. 1800RESPECT
20. HealthDirect — PTSD
21. ABS — National Study of Mental Health and Wellbeing
22. SafeScript Victoria